Nabriva Therapeutics (FRA:NTY) Days Inventory : 91.85 (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Nabriva Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Nabriva Therapeutics's Average Total Inventories for the three months ended in Jun. 2023 was €8.43 Mil. Nabriva Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2023 was €8.38 Mil. Hence, Nabriva Therapeutics's Days Inventory for the three months ended in Jun. 2023 was 91.85.

The historical rank and industry rank for Nabriva Therapeutics's Days Inventory or its related term are showing as below:

FRA:NTY' s Days Inventory Range Over the Past 10 Years
Min: 143.12 Med: 916.02 Max: 3556.14
Current: 143.12

During the past 10 years, Nabriva Therapeutics's highest Days Inventory was 3556.14. The lowest was 143.12. And the median was 916.02.

FRA:NTY's Days Inventory is ranked better than
62.23% of 654 companies
in the Biotechnology industry
Industry Median: 192.63 vs FRA:NTY: 143.12

Nabriva Therapeutics's Days Inventory declined from Jun. 2022 (312.79) to Jun. 2023 (91.85).

Inventory Turnover measures how fast the company turns over its inventory within a year. Nabriva Therapeutics's Inventory Turnover for the three months ended in Jun. 2023 was 0.99.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Nabriva Therapeutics's Inventory-to-Revenue for the three months ended in Jun. 2023 was 3.55.

Nabriva Therapeutics Days Inventory Historical Data

The historical data trend for Nabriva Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Days Inventory Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Inventory

Get a 7-Day Free Trial

3,557.30

1,567.06

276.46

148.63

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Days Inventory	Get a 7-Day Free Trial															312.79	329.42	78.76	193.34	91.85

Competitive Comparison of Nabriva Therapeutics's Days Inventory

For the Biotechnology subindustry, Nabriva Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Days Inventory falls into.

Nabriva Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Nabriva Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2022 is calculated as

	Days Inventory (A: Dec. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (12.84	+	9.134)	/	2 )	/	26.981	*	365
=	10.987					/	26.981	*	365
=	148.63

Nabriva Therapeutics's Days Inventory for the quarter that ended in Jun. 2023 is calculated as:

	Days Inventory (Q: Jun. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Mar. 2023 )	+	Total Inventories (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (8.431	+	0)	/	1 )	/	8.376	*	365 / 4
=	8.431					/	8.376	*	365 / 4
=	91.85

Nabriva Therapeutics (FRA:NTY) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Nabriva Therapeutics's Inventory Turnover for the three months ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	8.376	/	8.431
	=	0.99

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Nabriva Therapeutics's Inventory to Revenue for the three months ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	8.431	/	2.376
	=	3.55

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Nabriva Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (FRA:NTY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (FRA:NTY) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

NBRVF:USA

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Nabriva Therapeutics (FRA:NTY) Headlines

No Headlines